DC
GSK icon

Davenport & Co’s GSK GSK Stock Holding History

Davenport & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$821K Sell
15,656
-1,123
-7% -$59.4K ﹤0.01% 836
2026
Q1 		$926K Sell
16,779
-74,432
-82% -$4.03M 0.01% 740
2025
Q4 		$4.47M Sell
91,211
-17,430
-16% -$813K 0.02% 365
2025
Q3 		$4.69M Buy
108,641
+4,573
+4% +$179K 0.03% 353
2025
Q2 		$4M Buy
104,068
+87,412
+525% +$3.34M 0.02% 362
2025
Q1 		$645K Sell
16,656
-668
-4% -$24.5K ﹤0.01% 757
2024
Q4 		$586K Sell
17,324
-723
-4% -$26K ﹤0.01% 777
2024
Q3 		$738K Sell
18,047
-1,009
-5% -$41.3K ﹤0.01% 705
2024
Q2 		$734K Sell
19,056
-8,699
-31% -$366K ﹤0.01% 695
2024
Q1 		$1.19M Sell
27,755
-3,767
-12% -$155K 0.01% 573
2023
Q4 		$1.17M Sell
31,522
-343
-1% -$12.3K 0.01% 541
2023
Q3 		$1.16M Sell
31,865
-1,829
-5% -$64.9K 0.01% 504
2023
Q2 		$1.2M Buy
33,694
+4,833
+17% +$173K 0.01% 507
2023
Q1 		$1.03M Sell
28,861
-2,016
-7% -$70.5K 0.01% 527
2022
Q4 		$1.08M Buy
30,877
+3,084
+11% +$103K 0.01% 488
2022
Q3 		$818K Sell
27,793
-4,683
-14% -$177K 0.01% 542
2022
Q2 		$1.77M Buy
32,476
+3,694
+13% +$204K 0.01% 384
2022
Q1 		$1.57M Buy
28,782
+852
+3% +$46.3K 0.01% 442
2021
Q4 		$1.54M Buy
27,930
+1,019
+4% +$53K 0.01% 462
2021
Q3 		$1.28M Buy
26,911
+1,055
+4% +$53K 0.01% 483
2021
Q2 		$1.29M Buy
25,856
+2,254
+10% +$108K 0.01% 425
2021
Q1 		$1.05M Sell
23,602
-1,296
-5% -$58.8K 0.01% 384
2020
Q4 		$1.15M Buy
24,898
+966
+4% +$44.4K 0.01% 346
2020
Q3 		$1.13M Sell
23,932
-983
-4% -$49.3K 0.01% 321
2020
Q2 		$1.27M Sell
24,915
-711
-3% -$36.5K 0.02% 293
2020
Q1 		$1.21M Buy
25,626
+892
+4% +$47.6K 0.02% 268
2019
Q4 		$1.45M Sell
24,734
-2,482
-9% -$138K 0.02% 291
2019
Q3 		$1.36M Sell
27,216
-630
-2% -$32.4K 0.02% 287
2019
Q2 		$1.39M Sell
27,846
-4,874
-15% -$245K 0.02% 282
2019
Q1 		$1.71M Buy
32,720
+12,152
+59% +$607K 0.02% 249
2018
Q4 		$982K Sell
20,568
-1,692
-8% -$83.3K 0.01% 291
2018
Q3 		$1.12M Sell
22,260
-6,525
-23% -$332K 0.01% 309
2018
Q2 		$1.45M Sell
28,785
-30
-0.1% -$1.51K 0.02% 277
2018
Q1 		$1.41M Buy
28,815
+5,824
+25% +$271K 0.02% 271
2017
Q4 		$1.02M Sell
22,991
-4,263
-16% -$197K 0.01% 315
2017
Q3 		$1.38M Sell
27,254
-1,832
-6% -$92.9K 0.02% 265
2017
Q2 		$1.57M Sell
29,086
-723
-2% -$38.5K 0.02% 245
2017
Q1 		$1.43M Sell
29,809
-353
-1% -$17.9K 0.02% 243
2016
Q4 		$1.45M Sell
30,162
-3,020
-9% -$149K 0.02% 238
2016
Q3 		$1.79M Buy
33,182
+1,684
+5% +$92.3K 0.03% 217
2016
Q2 		$1.71M Sell
31,498
-2,495
-7% -$131K 0.03% 218
2016
Q1 		$1.72M Sell
33,993
-513
-1% -$25.6K 0.03% 216
2015
Q4 		$1.74M Sell
34,506
-984
-3% -$50.2K 0.03% 212
2015
Q3 		$1.71M Sell
35,490
-2,419
-6% -$126K 0.03% 216
2015
Q2 		$1.97M Sell
37,909
-1,281
-3% -$72.1K 0.03% 217
2015
Q1 		$2.26M Sell
39,190
-232
-0.6% -$13.3K 0.03% 213
2014
Q4 		$2.11M Sell
39,422
-10,016
-20% -$560K 0.03% 209
2014
Q3 		$2.84M Sell
49,438
-662,937
-93% -$40.6M 0.05% 182
2014
Q2 		$47.6M Buy
712,375
+9,121
+1% +$617K 0.81% 38
2014
Q1 		$47M Buy
703,254
+20,572
+3% +$1.39M 0.85% 31
2013
Q4 		$45.6M Buy
682,682
+13,279
+2% +$861K 0.85% 33
2013
Q3 		$42M Buy
669,403
+5,544
+0.8% +$357K 0.87% 38
2013
Q2 		$41.5M Buy
+663,859
New +$42.1M 0.91% 35

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return
KIC
Keating Investment Counselors Delray Beach, Florida $364M AUM 22.11% 1-Year Est. Return

Davenport & Co's GSK Position: Q2 2026 in Review

Davenport & Co reduced its GSK (GSK) stake by 6.7% in Q2 2026, selling an estimated $59.4K and leaving 15,656 shares worth $821K. The position accounts for ﹤0.01% of the portfolio, ranked #836.

Davenport & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $47.6M in Q2 2014. 188 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Davenport & Co held 15,656 shares of GSK worth $821K as of Q2 2026.
  • Davenport & Co sold 1,123 GSK shares in Q2 2026, an estimated $59.4K.
  • GSK made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #836 holding.
  • Davenport & Co first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
  • Davenport & Co's GSK position peaked at $47.6M in Q2 2014.
  • 188 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.